Catalent, the drug delivery technology provider, has signed an agreement with a German biotech company to support the manufacturing of a therapy product, it announced Monday.
Somerset-based Catalent will support Trizell GmbH’s Phase 1 cell therapy for the treatment of micro- and microangiopathies, it said in a news release. Manufacturing of the cell therapy will take place at Catalent’s facility in Gosselies, Belgium.
“Our relationship with Trizell will build on Catalent’s deep knowledge in immunotherapies, from the diagnosis and de-risk stage all the way through to commercial-ready processes,” Manja Boerman, president, Catalent Cell & Gene Therapy, said in a prepared statement. “Extending in to areas such as macrophages allows us to stay on the forefront of emerging indications and cell types.”